Skip to content

Evaluation of continuous noninvasive blood glucose measurement based on big data modeling-new technology for prevention and control of diabetes mellitus

Evaluation of continuous noninvasive blood glucose measurement based on big data modeling-new technology for prevention and control of diabetes mellitus

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400093042
Enrollment
Unknown
Registered
2024-11-27
Start date
2024-11-30
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus

Interventions

Gold Standard:Invasive fingertip blood glucose as the gold standard
Index test:Non-invasive blood glucose monitoring equipment

Sponsors

Beijing Physical Examination Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Diabetic patients: according to the diagnostic criteria of diabetes mellitus, patients with type 2 diabetes mellitus diagnosed by endocrinologists; or taking diabetes medication; or fasting venous glucose of not less than 7.0 mmol/L; or random glucose of not less than 11.1 mmol/L; or 2-hour glucose of not less than 11.1 mmol/L in the oral glucose tolerance test (OGTT); or glycosylated haemoglobin of more than 6%; and informed consent to participate voluntarily. Haemoglobin greater than 6.5%; and informed consent and voluntary participation 2. Pre-diabetes: fasting venous blood glucose between 6.1~6.9mmol/L; and oral glucose tolerance test (OGTT) 2-hour blood glucose between 7.8~11.0mmol/L; or glycated haemoglobin between 5.7~6.4%; and informed consent, voluntary participation 3. Normal population: Normal physical examination population, in line with the principle of informed consent and voluntary participation

Exclusion criteria

Exclusion criteria: Patients with primary psychiatric disorders with limited language communication; patients with surgery or history of major trauma in the previous 3 months; patients with severe acute illnesses such as dehydration and shock; patients with abnormalities of glucose metabolism, high blood lipids (TC>600mg/dl, TG>750mg/dl), and elevated bilirubin (total bilirubin>20mg/dl); and patients with a place of residence other than Beijing

Design outcomes

Primary

MeasureTime frame
20/20% concordance of the reference value;Proportion of measurement points falling in A+B zone of Clarke error raster analysis;Proportion of measurement points falling in the A+B zone of the Consensus error raster analysis;Mean Absolute Relative Error Value (MARD%);

Countries

China

Contacts

Public ContactGuo Xiuhua

Capital Medical University

statguo@ccmu.edu.cn+86 136 6128 3546

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026